Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 376

Document Document Title
JP2023040180A
To provide new and improved neuroactive steroids that modulate brain excitability for the prevention and treatment of CNS-related conditions.The invention provides compounds represented by formula (I) and pharmaceutically acceptable salt...  
JP7241792B2
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...  
JP2022044802A
To provide neuroactive steroids, compositions, and uses thereof.Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; and b) a...  
JP2022510683A
As used herein, equation (I) :. [During the ceremony, R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, And Q are as defined herein. L is selected from the group consisting of the above (whe...  
JP6873488B2
Provided is a method for manufacturing carboxylic acid or a salt thereof under a moderate condition and in a simple, highly-selective, high-yielding manner. Provided is a method for manufacturing a compound represented by general formula...  
JP6852118B2
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...  
JP2021008504A
To provide compounds and pharmaceutical compositions useful for prevention and treatment of CNS-related conditions.Compounds of a formula (I) in the figure are provided, where Z is selected from, e.g., a substituted or unsubstituted C1-C...  
JP6781148B2
The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds.  
JP2020523357A
Strong soft corticosteroids, pharmaceutical compositions containing them, and methods for use as anti-inflammatory agents. Also, a way to soften fluticasone propionate and similar corticosteroids to reach a powerful but safer alternative...  
JP2020062050A
To provide neuroactive steroids, compositions, and uses thereof.Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; and b) a...  
JP6453337B2
The present invention relates to a new stereoselective process for the synthesis of 17(α)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(α)-17-acetyl-17-hy droxy-estr-4-e...  
JP2017031161A
To provide a novel crystallization process for preparing fluticasone propionate as crystalline form 1 polymorph having controlled particle size and being suitable for micronization.The novel crystallization process comprises the step of ...  
JP2016505038A
The present invention is a novel compound and composition of 11β-hydroxysteroids, as well as pharmaceuticals for preventing or reversing mitochondrial damage in human or animal subjects, for treating or preventing diseases associated wi...  
JP5808830B2
A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowi...  
JP2014520848A
The invention relates to a novel crystallisation process for preparing fluticasone propionate as crystalline form 1 polymorph with controlled particle size and suitable for micronisation. Said process comprises the step of dissolving flu...  
JP5281291B2
The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalkyl which optionally may be substituted with a C1-C4 alkyl group; R2 represents hydr...  
JP5232083B2
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...  
JP2012528140A
This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to t...  
JP4838493B2
There is provided a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I)or a solvate thereof.  
JP4838494B2
A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) a glucocorticoid of formula (I) wherein R represents a 5 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N ...  
JP4749550B2
Androgenic steroids having a (14beta,17alpha-)-17-(hydroxymetheyl) configuration, useful for the preparation of male contraceptives and pharmaceutical formulations for the treatment of androgen insufficiency.  
JP4719144B2
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of —OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide ...  
JP2011121972A
To provide fluticasone formulations which can decrease a frequency of dosing, improve clinical efficacy, and potentially reduce side effects.A fluticasone composition formulated for administration selected from the group consisting of or...  
JP4709751B2
A process for preparing a compound of formula (I): wherein X represents O or S; R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl or C 3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl g...  
JP4709752B2
A process for preparing a compound of formula (I): wherein X represents O or S; R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl or C 3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl g...  
JP4698773B2
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...  
JP2011093929A
To provide a new compound which is an androstane-type glucocorticoid receptor agonist.The compound is expressed by formula (I) (in the formula, X is O or S; R1 is 1-6C alkyl, 3-8C cycloalkyl, 3-8C cycloalkylmethyl, 3-8C cycloalkenyl or t...  
JP2011507878A
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: wherein L, R1, R2, R3, R4, R5, and R6 are...  
JP2010280701A
To provide a pharmaceutical formulation for administration by inhalation having a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract.The pharmaceutical formulation containing a compound of f...  
JP4598268B2
The invention provides sterile glucocorticosteroids and sterile formulations containing glucocorticosteroid and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or the lungs.  
JP2010529174A
The 17β-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, in which...  
JP2010529153A
The 17β-cyano-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, in w...  
JP4508651B2
There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilized by the presence of a guest molecule, characterized in that the crystalline complex is of space group P212121 having u...  
JP4490689B2
Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the fun...  
JP4450435B2
The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor...  
JP2010070567A
To provide a method for sterilizing a powdery form glucocorticosteroid, sterile glucocorticosteroid, sterile formulation containing glucocorticosteroid, and use thereof for treating an allergic and/or inflammatory condition of the nose o...  
JP4417838B2
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...  
JP4331478B2
The invention relates to a process for the production of 4-(17alpha-methyl-substituted 3-oxoestra-4,9-dien-11beta-yl)benzaldehyde-(1E or 1Z)-oximes of general formula (I), in which R1 is a hydrogen atom, a C1-6-alkyl radical or a CnF2n+1...  
JP2009515844A
The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched chain alkyl, C3-C8 cycloalkyl optionally substituted by one or more groups independently selected from C1-C3 alkyl and methoxy, C4-C6 cyc...  
JP4187437B2
A compound having the structure: wherein n is an integer from 1-5; each of R1 and R2 independently is optionally substituted C1-C6 alkyl; each of W and X is independently hydrogen or C1-C6 alkyl; Y is O, S or NR3 where R3 is hydrogen, C1...  
JP2008526807A
The present invention is directed to compounds of formula (I): wherein R1 represents a 1,1-dimethylethyl group or a 1,1-dimethylpropyl group and physiologically acceptable solvates thereof, physiologically functional derivatives thereof,...  
JP4095018B2
A process for the preparation of high purity flumethasone in high yield involves C3 protecting 9,11beta-epoxy-17alpha,21-dihydroxy-16alpha-methylpregna-1,4 -diene-3,20-dione,21-acetate, fluorinating at 6alpha, removing the C3 protecting ...  
JP2008120839A
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.  
JP2008120840A
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.  
JP4089181B2  
JP4065399B2
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals  
JP2007534757A
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...  
JP2007302684A
To provide a compound for use in the treatment of an inflammatory or obstructive airway disease, a method for producing the same, and a medicament containing the same. Provided is a medicament comprising, separately or together, (A) a co...  
JP2007529426A
Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CC...  
JP2007527381A
The invention relates to a novel procedure for the production of a high yield of small crystalline particles of a narrow size distribution.  

Matches 151 - 200 out of 376